Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II erdafitinib in advanced non-small cell lung cancer with FGFR alterations
2018-000399-13Phase 2Terminated
- Sponsor
- University of Cologne
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erdafitinib in non-small cell lung cancer (NSCLC), sponsored by University of Cologne. Primary endpoint: Overall response rate. Started Oct 2018; status: terminated.
02
Drugs
erdafitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-000399-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000399-13.